-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, on March 24, 2022, the drug approval certificate pending information release, a total of 17 varieties have passed/deemed to pass the consistency of generic drugs, of which 4 varieties are injections/injectable drugs, including injection Cefoperazone Sodium Sulbactam Sodium (Lijian Pharmaceutical), Arginine Glutamate Injection (Haisco), Cefepime Hydrochloride for Injection (Xinfeng Pharmaceutical), Gadobutrol Injection (Hengrui Pharmaceutical), and There are 2 varieties that have been reviewed by the head home
.
Arginine and glutamic acid injection head home review Arginine and glutamic acid, as an adjuvant drug for lowering blood ammonia, is mainly used for the adjuvant treatment of elevated blood ammonia caused by chronic liver disease
.
It is understood that Haisco's arginine glutamic acid injection was approved for listing in China in 2016, and entered the National Medical Insurance Catalogue (Class B) in 2019, with a price drop of more than 84.
5%
.
At present, Haisco occupies most of the market share of this variety in China.
In 2019, the sales revenue of sample hospitals was 38.
64 million yuan, a year-on-year increase of 11.
47%
.
Haisco has been the first company to evaluate this product.
After passing the consistency evaluation, it will enjoy favorable policy support, which will help bring positive influence to the company
.
Gadobutrol injection has been reviewed by the first homemaker.
The original research company of gadobutrol is Bayer
.
According to Bayer's financial report, the global sales of gadobutrol injection in 2019 reached US$440 million, a year-on-year increase of 9%
.
Bayer has dominated the domestic market for many years
.
According to data from Minet.
com, the sales volume of gadobutrol injection in sample hospitals in 2021 will exceed 40 million yuan, a year-on-year increase of 56.
01%
.
Hengrui Medicine applied for the product listing as early as 2012, and was officially included in the priority review in July 2016, but was told "not approved" in April 2020
.
A month later, Hengrui once again submitted a new 4-type generic drug listing application, and the first generic drug was approved recently, and the first one was deemed to have passed the review
.
At present, pharmaceutical companies including Beilu Pharmaceutical, Hunan Kelun, and Yangzijiang have also submitted applications for the registration of gadobutrol injection, which are currently under review and approval
.
Cefoperazone Sodium and Sulbactam Sodium for Injection No.
3 Review Cefoperazone Sodium and Sulbactam Sodium for Injection is a large variety of antibacterial drugs, mainly used to treat infections caused by sensitive bacteria
.
The product has a broad market prospect.
According to data from Minet.
com, the sales of cefoperazone-sulbactam injection in China's public medical institutions will exceed 6 billion yuan in 2020, and the first half of 2021 will increase by nearly 6% year-on-year, of which Pfizer accounts for more than 80%
.
At present, in addition to Lijian Pharmaceuticals, Suzhou Dawnrays Pharmaceuticals and Shandong Runze Pharmaceuticals have been reviewed for this product
.
Among them, Suzhou Dawnrays Pharmaceutical is the first company that has reviewed the product
.
Cefepime hydrochloride for injection has been evaluated by 10 companies.
Cefepime is a broad-spectrum antibacterial drug, and its mechanism of action is to inhibit the synthesis of bacterial cell walls to achieve sterilization
.
Cefepime for injection can be used to treat moderate to severe infections caused by sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple and complex urinary tract infections (including pyelonephritis), Empirical treatment of uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), gynecologic infections, sepsis, and neutropenia in patients with fever, and as prophylaxis in patients undergoing abdominal surgery Sexual medication, and for bacterial meningitis in children
.
According to the data of Minet.
com, the annual sales trend of sample hospitals in China (urban public) in 2020 shows that the sales volume of cefepime hydrochloride for injection is 24,500 yuan
.
At present, including Xinfeng Pharmaceutical, the number of companies that have passed the evaluation of this variety has reached 10.
Previously, Yuekang Pharmaceutical's cefepime for injection also passed the consistency evaluation of generic drugs
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Arginine and glutamic acid injection head home review Arginine and glutamic acid, as an adjuvant drug for lowering blood ammonia, is mainly used for the adjuvant treatment of elevated blood ammonia caused by chronic liver disease
.
It is understood that Haisco's arginine glutamic acid injection was approved for listing in China in 2016, and entered the National Medical Insurance Catalogue (Class B) in 2019, with a price drop of more than 84.
5%
.
At present, Haisco occupies most of the market share of this variety in China.
In 2019, the sales revenue of sample hospitals was 38.
64 million yuan, a year-on-year increase of 11.
47%
.
Haisco has been the first company to evaluate this product.
After passing the consistency evaluation, it will enjoy favorable policy support, which will help bring positive influence to the company
.
Gadobutrol injection has been reviewed by the first homemaker.
The original research company of gadobutrol is Bayer
.
According to Bayer's financial report, the global sales of gadobutrol injection in 2019 reached US$440 million, a year-on-year increase of 9%
.
Bayer has dominated the domestic market for many years
.
According to data from Minet.
com, the sales volume of gadobutrol injection in sample hospitals in 2021 will exceed 40 million yuan, a year-on-year increase of 56.
01%
.
Hengrui Medicine applied for the product listing as early as 2012, and was officially included in the priority review in July 2016, but was told "not approved" in April 2020
.
A month later, Hengrui once again submitted a new 4-type generic drug listing application, and the first generic drug was approved recently, and the first one was deemed to have passed the review
.
At present, pharmaceutical companies including Beilu Pharmaceutical, Hunan Kelun, and Yangzijiang have also submitted applications for the registration of gadobutrol injection, which are currently under review and approval
.
Cefoperazone Sodium and Sulbactam Sodium for Injection No.
3 Review Cefoperazone Sodium and Sulbactam Sodium for Injection is a large variety of antibacterial drugs, mainly used to treat infections caused by sensitive bacteria
.
The product has a broad market prospect.
According to data from Minet.
com, the sales of cefoperazone-sulbactam injection in China's public medical institutions will exceed 6 billion yuan in 2020, and the first half of 2021 will increase by nearly 6% year-on-year, of which Pfizer accounts for more than 80%
.
At present, in addition to Lijian Pharmaceuticals, Suzhou Dawnrays Pharmaceuticals and Shandong Runze Pharmaceuticals have been reviewed for this product
.
Among them, Suzhou Dawnrays Pharmaceutical is the first company that has reviewed the product
.
Cefepime hydrochloride for injection has been evaluated by 10 companies.
Cefepime is a broad-spectrum antibacterial drug, and its mechanism of action is to inhibit the synthesis of bacterial cell walls to achieve sterilization
.
Cefepime for injection can be used to treat moderate to severe infections caused by sensitive bacteria in adults and children aged 2 months to 16 years, including lower respiratory tract infections (pneumonia and bronchitis), simple and complex urinary tract infections (including pyelonephritis), Empirical treatment of uncomplicated skin and skin and soft tissue infections, complicated intra-abdominal infections (including peritonitis and biliary tract infections), gynecologic infections, sepsis, and neutropenia in patients with fever, and as prophylaxis in patients undergoing abdominal surgery Sexual medication, and for bacterial meningitis in children
.
According to the data of Minet.
com, the annual sales trend of sample hospitals in China (urban public) in 2020 shows that the sales volume of cefepime hydrochloride for injection is 24,500 yuan
.
At present, including Xinfeng Pharmaceutical, the number of companies that have passed the evaluation of this variety has reached 10.
Previously, Yuekang Pharmaceutical's cefepime for injection also passed the consistency evaluation of generic drugs
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
